Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Citi
Cipla
Johnson and Johnson
Chubb
Fish and Richardson

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,465,504

« Back to Dashboard

Summary for Patent: 6,465,504
Title: Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Abstract:The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I ##STR1## in which R.sub.1 -R.sub.5 are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.
Inventor(s): Lattmann; Rene (Binningen, SE), Acklin; Pierre (Basel, SE)
Assignee: Novartis AG (Basel, CH)
Application Number:09/699,765
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,465,504
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,465,504
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,465,504

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-001 May 18, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-002 May 18, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-003 May 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-001 Nov 2, 2005 AB RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,465,504

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden1593/96Jun 25, 1996

International Family Members for US Patent 6,465,504

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1127 ➤ Sign Up
African Regional IP Organization (ARIPO) 9801407 ➤ Sign Up
Argentina 007479 ➤ Sign Up
Austria 226435 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
Mallinckrodt
Baxter
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.